Creative Biolabs Assists in Developing Vaccines Against SARS-CoV-2

New York, USA – March 7, 2023 – What caused consternation was a new study published in The Lancet that immunity from COVID-19 infection provides strong, long-lasting protection against the severe consequences of the illness at levels as high as, or even higher than that provided by mRNA vaccines.

“Although it’s a fact, vaccine development is essential, considering many uninfected vulnerable people with underlying diseases. It is of vital significance to advance the creation of quality vaccines,” a scientist at Creative Biolabs stated.

Deeply involved in vaccine and antiviral drug discoveries against coronaviruses, the services of Creative Biolabs specifically for SARS-CoV-2 prevention methods cover the mainstream and novel vaccine types on the market, such as:

In Silico Vaccine

The platform contains epitope screening tools to identify epitopes with high potentials, such as prediction of peptide/HLA binding and HLA class I CD8+ and CD4+ T cell epitopes and examine conserved regions in multiple SARS-CoV-2 strains to achieve maximum coverage.

“Combining in silico results with in vitro assays, the platform is quite productive to lock up candidates with strong potential,” commented the scientist, “and our team will facilitate the analysis and interpretation of reports and provide help throughout the process.”

Virus-like Particle-based Vaccine

The solution features Creative Biolabs’ access to a variety of VLP expression systems, such as mammalian cells (293T, CHO), yeast, recombinant vaccinia virus, and baculovirus expression systems, which act as powerful engines to source SARS-CoV-2 virus like particles for the development of vaccines against S, M, and E proteins.

Creative Biolabs develops formulation optimization for SARS-CoV-2 vaccine in response to the imminent need to improve potency and cut down side-effects of licensed COVID-19 vaccines and provides quality services for rational vaccine design. The offered assistants compose adjuvant optimization, delivery system optimization, and formulation parameter optimization.

“In addition to continuing intensive vaccine development, emphasis should be placed on studying antiviral drugs against SARS-CoV-2.”

Creative Biolabs develops evaluation platforms for SARS-CoV-2 drugs, which enable global clients to assess their candidates through reverse genetics systems, protease inhibitor assay, study of cytokine responses in SARS-CoV-2 infection, immunofluorescence-based antiviral assay, etc., to safeguard drug discovery.

The above is only a brief description and not a complete list. For detailed information, please feel free to consult the website https://sars-cov-2.creative-biolabs.com.

About Creative Biolabs

Creative Biolabs, a CRO dedicated to the research on SARS-CoV-2, has rich experience in vaccine and antiviral drug discovery. In response to the increasingly challenging SARS-CoV-2 infection situation, Creative Biolabs delivers superb data to provide our clients with the most satisfactory drug discovery and vaccine discovery services.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://sars-cov-2.creative-biolabs.com